Fox Chase Cancer Center research reveals how COX-2 causes ovarian cancer

owel cancer.

The important role of inheritance has led many women with a family history of breast or ovarian cancer to have their breasts and ovaries removed as a means of preventing the development of cancer. Xu and his colleagues studied the tissues removed during prophylactic oophorectomy (removal of the ovaries) for clues about the precancerous changes that go on in the cells.

One of the cell proteins they analyzed was COX-2, a physiologically important enzyme that plays a role in ovulation as well as in antibacterial, immunologic and inflammatory processes. COX-2 has also been shown to stimulate tumor cell division and angiogenesis (new blood vessel formation) and to inhibit a type of programmed cell death called apoptosis, which helps control the growth of tumors. Xu's analysis of the ovarian tissue specimens showed that as the level of COX-2 increases, it appears to promote the loss of basement membrane.

Treatment with COX-2 inhibitors may prevent the development of cancer cells. In fact, the National Cancer Institute will launch a human clinical trial of COX-2 inhibitors. Mary B. Daly, M.D., Ph.D., director of Fox Chase's Cancer Control Program, is heading the multi-center trial, which will include Fox Chase as one of its sites. Fox Chase has one of four Specialized Programs of Research Excellence (SPORE) in Ovarian Cancer, established by the NCI in 1999.

Understanding what happens in ovarian cells before they become cancerous is important not only because it may lead to preventive therapies but also because it may lead to the identification of markers of the disease that will be useful for diagnosis and for assessing treatment results. One of the reasons for the high death rate among women who develop ovarian cancer is that diagnosis often is delayed until late stages of the disease.

In addition to Xu and Daly, the Fox Chase research team includes Isabelle H. Roland, Wan-Lin Yang, Ph.D., Dong-Hua Yang, M.D., Ph.D., Robert F.

Contact: Karen Carter Mallet
Fox Chase Cancer Center

Page: 1 2 3

Related biology news :

1. Fox Chase Cancer Centers Alfred Knudson Jr. named 2004 Kyoto Prize winner
2. Fox Chase discovery may help physicians diagnose, treat devastating childhood disease
3. Wilex & Fox Chase Cancer Center begin trial w/ novel compound targeting tumor invasion & metastasis
4. Fox Chase Cancer Center research shows kidney cancer can be diagnosed in urine
5. Fox Chase Cancer Center researchers identify significant smoking-induced genetic alteration
6. Fox Chase Cancer Center research shows kidney cancer can be diagnosed in urine
7. Fox Chase Cancer Center researcher develops new model for studying prions mad cow disease
8. Fox Chase Cancer Center study: Novel DNA-repair gene mutation can cause resistance to cancer drugs
9. NIH funds Breast Cancer and the Environmental Research Center at Fox Chase Cancer Center
10. Fox Chase Cancer Center researchers make significant discovery about function of p53
11. Fox Chase Cancer Center receives grant to study possible link between measles vaccine and autism

Post Your Comments:

(Date:12/18/2019)... ... December 17, 2019 , ... PM360, a leading trade magazine ... has named Pharmafusion LLC as one of the most innovative startups of 2019. ... founder/CEO Jonathan Retano. Earlier in the year, Pharmafusion was featured as one of ...
(Date:12/14/2019)... ... 12, 2019 , ... Crop Enhancement Inc., an ... Jean Pougnier as chief business officer. Mr. Pougnier will lead the company’s efforts ... will position the company for maximum commercial success. As part of the expansion ...
(Date:12/4/2019)... ... December 04, 2019 , ... ... launched Subnovii Advanced Plasma Technology for U.S. dermatologists, plastic surgeons and ... the only plasma to employ LF technology – low frequency plus a patented ...
Breaking Biology News(10 mins):
(Date:12/30/2019)... TOWNSHIP, N.J. (PRWEB) , ... December 30, 2019 ... ... of custom built, helium-based leak testing instruments for the Pharmaceutical, Biotechnology, Medical Device ... SIMS Version 1.11.19 21 CFR Part 11 compliant software program specific to the ...
(Date:12/18/2019)... ... December 17, 2019 , ... Philadelphia ... to announce that it has hired Dr. Alia Orbin, Ph.D., J.D., an experienced ... in the preparation, filing and prosecution of patent applications related to pharmaceutical sciences, ...
(Date:12/4/2019)... United Kingdom (PRWEB) , ... December 03, 2019 ... ... of recombinant antibody products and services, today announced a partnership with the Recombinant ... Chicago, University of Toronto, and UC San Francisco (UCSF) with a common goal ...
(Date:12/2/2019)... ... December 02, 2019 , ... Registration is now ... Meeting, which will be held at the Hynes Convention Center May 12-15, 2020, in ... therapy and brings together scientists, physicians, patient advocates, and other stakeholders with the goal ...
Breaking Biology Technology:
Cached News: